Cytokinetics lead product
WebApr 11, 2024 · 12 analysts have issued twelve-month price targets for Cytokinetics' shares. Their CYTK share price forecasts range from $15.00 to $80.00. On average, they expect the company's stock price to reach $56.21 in the next year. This suggests a possible upside of 54.4% from the stock's current price. View analysts price targets for CYTK or view top ... WebHeadquarters United States of America. Address ., 280 East Grand Avenue, South San Francisco, California, 94080. Website cytokinetics.com. Telephone 1 650 6243000. No of Employees 253. Industry Pharmaceuticals and Healthcare. Ticker Symbol & Exchange CYTK (NASD) Revenue (2024) $70.4M 26.2% (2024 vs 2024) EPS XXX.
Cytokinetics lead product
Did you know?
WebOct 18, 2016 · Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator, for the potential treatment of ALS. Tirasemtiv has been granted … WebMar 29, 2024 · SOUTH SAN FRANCISCO, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that the second cohort of the Phase 2 clinical trial of CK-2127107 in patients...
WebJul 19, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in … WebApr 10, 2024 · SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2024 at 10:00 …
WebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments … WebMar 2010 - May 20122 years 3 months. Greater Philadelphia Area. US Marketing Lead for a $3 billion portfolio of in-line products, including …
WebCytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential …
WebFeb 27, 2024 · Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and... churrupearWebApr 13, 2024 · The projected fair value for Cytokinetics is US$38.04 based on 2 Stage Free Cash Flow to Equity. Cytokinetics' US$34.05 share price indicates it is trading at similar levels as its fair value estimate dfo groundfishWebOct 20, 2014 · SOUTH SAN FRANCISCO, CA, October 20, 2014 - Cytokinetics, Incorporated ( CYTK) provided a program update today relating to tirasemtiv, the company`s lead drug candidate from its skeletal muscle... churrucaWebFeb 24, 2024 · Cytokinetics’ vision: With more than 25 years of science behind its mission to advance muscle biology-driven treatments for diseases characterized by compromised … dfo groundfish formsWebApr 11, 2024 · Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on the development of novel immunotherapies to treat and prevent cancer ... dfo gulf csasWebApr 6, 2024 · Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' … dfo groundfish ifmpWebFeb 28, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in … dfo groundfish management areas pacific